Geeta Vemuri
Co-Founder & Managing Partner @ Agent Capital
Boston, United States
Geeta Vemuri is a seed investor at Agent Capital in Boston focused on Biotechnology and Therapeutics. Geeta Vemuri joined Baxter in January, 2012 as VP, Head of Baxter Ventures, the corporation's $200 million venture fund. Prior to joining Baxter, she was a General Partner at Quaker Partners, where she spent her time leading investments in Biopharmaceutical and Healthcare companies and being integral part of the team in raising capital for thefunds. Dr. Vemuri's role in building and mentoring portfolio companies has helped lead their exit through either acquisition or through Initial Public Offering. Some of her representative Quaker portfolio board member or observer responsibilities include Protez, Cempra, Corridor, Regado and Tranzyme Pharma. Prior to Quaker, she was an Associate at Toucan Capital, where she was responsible for investments in seed-stage and start-up biotech opportunities. She participated in raising capital and helped start portfolio companies by identifying technologies from universities. Prior to that, she was an Associate Equity Analyst at SalomonSmithBarney and First Union Securities covering specialty pharmaceuticals and healthcare sectors. Geeta was also a research scientist at The Wistar Institute and completed her postdoctoral fellow program at Thomas Jefferson University. Dr. Vemuri received her M.S. from Central University in India, her Ph.D. in biochemistry from the Indian Institute of Sciences, and her M.B.A. from the Wharton School of the University of Pennsylvania.
- Total investments:
- 13
- Last investment:
- Lead investor:
- 23%
Last updated:
For AI agents: llms.txt
Industries Geeta Vemuri invests in
Stages Geeta Vemuri invests in
Countries Geeta Vemuri invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 7 (54%)
- Therapeutics 4 (31%)
- Health Care 3 (23%)
- Life Science 3 (23%)
- Medical 2 (15%)
Stage
- Seed 3 (23%)
- Series A 3 (23%)
- Series B 3 (23%)
- Funding Round 2 (15%)
- Series C 1 (8%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Interius BioTherapeutics
|
Interius BioTherapeutics is a biopharmaceutical company that targets cancer. The company spun out the University of Pennsylvania and is targeting cancer. | $21.5M / Jan 01, 2025 | |
Cantai Therapeutics
|
Cantai Therapeutics operates as a developer of drug candidates. | $700K / Seed / Nov 20, 2023 | |
Vittoria Biotherapeutics
|
Vittoria Biotherapeutics develops gene-edited cell therapies. they provide next-generation, paradigm-shifting T-cell therapeutics that address unmet medical needs. Senza5 Technology from viTToria improves the efficacy, safety, and utility of cell-based treatments in preclinical settings. | $15M / Nov 13, 2023 | |
Carisma Therapeutics
|
Carisma Therapeutics is a biotechnology company developing cellular immunotherapies to treat solid tumors. Its cell therapies apply powerful chimeric antigen receptor technology and adoptive cell transfer in cancer therapy and to macrophages that infiltrate the solid tumor micro-environment that enables solid tumor patients to receive strongcellular immunotherapy and cancer treatments. The company's technology leverages advances in macrophage biology, chimeric antigen receptor engineering, and adoptive cellular therapy for the treatment of human disease.Founded in 2016 by Michael Klichinsky and Saar Gill, Carisma Therapeutics is headquartered in Philadelphia, Pennsylvania. | $30M / Series C / Sep 21, 2022 | |
Carbon Biosciences
|
Carbon Biosciences develops genetic medicines for the treatment of devastating diseases. They develop their vector using industrial-scale viral production platforms and can be used to deliver a wide-range of therapeutic modalities. | $38M / Series A / Jun 21, 2022 | |
|
Vittoria Biotherapeutics
|
Vittoria Biotherapeutics develops gene-edited cell therapies. they provide next-generation, paradigm-shifting T-cell therapeutics that address unmet medical needs. Senza5 Technology from viTToria improves the efficacy, safety, and utility of cell-based treatments in preclinical settings. | $10M / Seed / Jun 07, 2022 | |
Cyrus Biotechnology
|
Cyrus Biotechnology builds software tools to accelerate basic research in biotech, pharma, and industrial biotechnology. Cyrus Bench delivers an enterprise version of the Rosetta molecular modeling and design toolkit, with the associated array of bio-molecular computation tools. It was founded in 2014 and headquartered in Seattle, Washington. | $18M / Series B / Dec 06, 2021 | |
Immunitas Therapeutics
|
Immunitas is unlocking human immunology using novel single cell analyses to develop targeted therapeutics for patients with challenging, complex cancers. Translating findings from laboratory research to meaningful clinical advances in humans is a longstanding challenge in the oncology field. Immunitas was founded to directly address this problemand unlock a variety of novel drug targets based on discovery rooted in human biology. They are pursuing this goal with a team of pioneers in these areas across their scientific founders, management, and investors.At Immunitas, they employ a single cell sequencing platform to dissect the biology of immune cells in human tumors. Their focus on human samples allows us to start with and stay closer to the most relevant and translatable biology for patients and accelerates the pace of their research. They are identifying novel, exciting oncology targets and, importantly, developing key biomarkers to guide the selection of patients who may benefit from their new drugs. They are leveraging expertise in antibody discovery and engineering to create powerful therapies that modulate these targets, and are currently advancing a number of programs toward early human studies. | $58M / Series B / Aug 18, 2021 | |
|
Interius BioTherapeutics
|
Interius BioTherapeutics is a biopharmaceutical company that targets cancer. The company spun out the University of Pennsylvania and is targeting cancer. | $76M / Series A / May 18, 2021 | |
|
Carisma Therapeutics
|
Carisma Therapeutics is a biotechnology company developing cellular immunotherapies to treat solid tumors. Its cell therapies apply powerful chimeric antigen receptor technology and adoptive cell transfer in cancer therapy and to macrophages that infiltrate the solid tumor micro-environment that enables solid tumor patients to receive strongcellular immunotherapy and cancer treatments. The company's technology leverages advances in macrophage biology, chimeric antigen receptor engineering, and adoptive cellular therapy for the treatment of human disease.Founded in 2016 by Michael Klichinsky and Saar Gill, Carisma Therapeutics is headquartered in Philadelphia, Pennsylvania. | $12M / Series B / Mar 01, 2021 | |
| See all 13 investments → | |||
Co-Investors
Penn Medicine Co-Investment Program
7 deals together
Tellus BioVentures
7 deals together
Longwood Fund
4 deals together
Solasta Ventures
4 deals together
The Mark Foundation for Cancer Research
4 deals together
BrightEdge Fund
3 deals together
About Agent Capital
A biotech venture capital firm.
Agent Capital Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Geeta Vemuri
Co-Founder & Managing Partner
|
|||
Preston Noon
Co-Founder & General Partner
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Geeta Vemuri invest in?
Geeta Vemuri invests primarily in Biotechnology, Therapeutics and Health Care startups, most often at Seed and Series A stage. Most of the 13 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Geeta Vemuri?
Public channels for Geeta Vemuri include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Geeta Vemuri last invest?
The most recent investment recorded for Geeta Vemuri closed in Jan 2025. Shizune tracks 13 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
